SARMs and peptides on TikTok: separating gym lore from evidence

What's this video probably claiming?

Based on the creator handle (@more.sarms.biggerr.arms), the Biaxol hashtag (a vendor known for selling SARMs and peptides), and the gymtok/bodybuilding context, this video is almost certainly promoting one or more of the following: SARMs like ostarine, LGD-4033, or RAD-140 as safer alternatives to anabolic steroids; peptides such as BPC-157 or TB-500 for recovery; or MK-677 (ibutamoren) as a growth hormone secretagogue for muscle gain. The framing is likely aspirational, meaning bigger arms, faster recovery, less suppression than steroids. Biaxol-affiliated content tends to present these compounds as accessible, low-risk performance tools. That framing should immediately raise flags for anyone who has read the actual adverse event literature.

What does the science actually show?

Start with SARMs. A 2023 FDA adverse event reporting analysis by Yee et al. (Drug Safety) documented liver injury, cardiovascular events, and hormonal suppression across multiple SARMs including LGD-4033 and RAD-140, with some cases requiring hospitalization. These are not fringe reports. A 2020 case series in the Annals of Internal Medicine described severe drug-induced liver injury in otherwise healthy young men using LGD-4033 purchased from online vendors. On peptides, BPC-157 has genuinely interesting rodent data for gut and tendon repair (Sikiric et al., 2018, Current Pharmaceutical Design), but zero completed randomized controlled trials in humans as of mid-2025. MK-677 showed modest lean mass increases in older adults at 25 mg/day over 12 months (Nass et al., 2008, Journal of Clinical Endocrinology and Metabolism), but also increased fasting glucose and caused significant water retention. The muscle gain numbers in that trial were not dramatic.

Where does the social media noise diverge from clinical reality?

The biggest gap is the suppression narrative. Gymtok routinely frames SARMs as non-suppressive or mildly suppressive compared to steroids. The clinical data disagrees. A 2023 study by Basaria et al. replicated in part by earlier work showed testosterone suppression exceeding 50 percent from baseline in some LGD-4033 users at doses as low as 1 mg/day. At the doses bodybuilders actually use, 5 to 20 mg/day, suppression is functionally equivalent to exogenous androgen use and requires post-cycle therapy. Biaxol-affiliated content rarely mentions this. Similarly, BPC-157 is presented as a proven recovery tool when the honest summary is: promising animal pharmacology, no peer-reviewed human efficacy trials, unknown long-term safety profile, and no regulatory approval anywhere. Calling it a peptide therapy implies clinical legitimacy that does not currently exist in the published literature.

What should you actually know?

SARMs are not approved by the FDA, EMA, or any major regulatory body for human use. They are explicitly banned by WADA. Purchasing them from vendors like Biaxol means you are buying a research chemical with no quality control oversight, no standardized dosing, and no liability framework if something goes wrong. A 2021 analysis by van Wagoner et al. (JAMA) found that 52 percent of products labeled as SARMs contained unapproved drugs, wrong doses, or unlisted compounds entirely. Peptides in this category, BPC-157, TB-500, MK-677, occupy a similarly grey zone. MK-677 is not a peptide but a small molecule ghrelin mimetic, a distinction vendors frequently blur. If you are considering any of these compounds, the conversation belongs with a licensed clinician who can order baseline labs, monitor hormonal panels, and actually review your cardiovascular and hepatic risk profile before you start.